Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Current Assets Liabilities and Shareholders Equity Non-Current Assets Other Accumulated Expenses Other Non-Current Assets Payables Prepaid Assets Receivables Retained Earnings Shareholder's Equity Short-term Investments Total Current Liabilities Total Liabilities

Daily Values

Growth Metrics

Income Statement

Others

Ratios

Anbio Biotechnology (NNNN) Liabilities and Shareholders Equity (2023 - 2025)

Anbio Biotechnology has reported Liabilities and Shareholders Equity over the past 3 years, most recently at $30.2 million for Q4 2025.